166 related articles for article (PubMed ID: 37869746)
1. Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations.
Cheng L; Luo M; Guo Y; Fan Y; Wang P; Zhou G; Qin S; Weng B; Li P; Liu Z; Liu S
Front Pharmacol; 2023; 14():1248331. PubMed ID: 37869746
[No Abstract] [Full Text] [Related]
2. Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots.
Herrera-Pérez IG; Rodríguez-Báez AS; Ortiz-Álvarez A; Velarde-Salcedo R; Arriaga-García FJ; Rodríguez-Pinal CJ; Romano-Moreno S; Milán-Segovia RDC; Medellín-Garibay SE
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Aug; 1228():123801. PubMed ID: 37453389
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
4. Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study.
Zhao G; Chen M; Sun L; Xi N
Ann Transl Med; 2022 Apr; 10(8):461. PubMed ID: 35571444
[TBL] [Abstract][Full Text] [Related]
5. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
Um SW; Lee SW; Kwon SY; Yoon HI; Park KU; Song J; Lee CT; Lee JH
Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
[TBL] [Abstract][Full Text] [Related]
7. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection.
Xing Y; Yin L; Le X; Chen J; Zhang L; Li Y; Lu H; Zhang L
Heliyon; 2021 Jul; 7(7):e07532. PubMed ID: 34296020
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: A preliminary study.
Ramachandran G; Hemanth Kumar AK; Kannan T; Thangakunam B; Shankar D; Christopher DJ
Indian J Med Res; 2023; 157(2&3):211-215. PubMed ID: 36861539
[TBL] [Abstract][Full Text] [Related]
10. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
[TBL] [Abstract][Full Text] [Related]
12. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Justine M; Yeconia A; Nicodemu I; Augustino D; Gratz J; Mduma E; Heysell SK; Kivuyo S; Mfinanga S; Peloquin CA; Zagurski T; Kibiki GS; Mmbaga B; Houpt ER; Thomas TA
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):14-20. PubMed ID: 30395239
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil.
Höfling CC; Pavan EM; Giampaglia CM; Ferrazoli L; Aily DC; de Albuquerque DM; Ramos MC
Int J Tuberc Lung Dis; 2005 Jan; 9(1):87-93. PubMed ID: 15675556
[TBL] [Abstract][Full Text] [Related]
15. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
[TBL] [Abstract][Full Text] [Related]
16. [Pyrazinamide versus ethambutol in short-term therapy of lung tuberculosis. A randomized study].
Fiala W; Häcki MA; Brändli O
Schweiz Med Wochenschr; 1983 Dec; 113(51):1956-9. PubMed ID: 6658432
[TBL] [Abstract][Full Text] [Related]
17. [Tuberculosis treatment today].
Nowak D; Radenbach D; Kirsten D; Magnussen H
Z Gesamte Inn Med; 1991 Aug; 46(10-11):404-9. PubMed ID: 1926948
[TBL] [Abstract][Full Text] [Related]
18. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
19. [Prevalence and transmission of pyrazinamide-resistant
Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
[No Abstract] [Full Text] [Related]
20. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
